{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:36:27Z","timestamp":1787168187580,"version":"build-2736575974"},"reference-count":133,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:p>\n                    The calcium-sensing receptor (CASR) is the main calcium sensor in the maintenance of calcium metabolism. Mutations of the\n                    <jats:italic>CASR<\/jats:italic>\n                    , the G protein alpha 11 (\n                    <jats:italic>GNA11<\/jats:italic>\n                    ) and the adaptor-related protein complex 2 sigma 1 subunit (\n                    <jats:italic>AP2S1<\/jats:italic>\n                    ) genes can shift the set point for calcium sensing causing hyper- or hypo-calcemic disorders. Therapeutic concepts for these rare diseases range from general therapies of hyper- and hypo-calcemic conditions to more pathophysiology oriented approaches such as parathyroid hormone (PTH) substitution and allosteric CASR modulators. Cinacalcet is a calcimimetic that enhances receptor function and has gained approval for the treatment of hyperparathyroidism. Calcilytics in turn attenuate CASR activity and are currently under investigation for the treatment of various diseases. We conducted a literature search for reports about treatment of patients harboring inactivating or activating CASR, GNA11 or AP2S1 mutants and about\n                    <jats:italic>in vitro<\/jats:italic>\n                    effects of allosteric CASR modulators on mutated CASR. The therapeutic concepts for patients with familial hypocalciuric hypercalcemia (FHH), neonatal hyperparathyroidism (NHPT), neonatal severe hyperparathyroidism (NSHPT) and autosomal dominant hypocalcemia (ADH) are reviewed. FHH is usually benign, but symptomatic patients benefit from cinacalcet. In NSHPT patients pamidronate effectively lowers serum calcium, but most patients require parathyroidectomy. In some patients cinacalcet can obviate the need for surgery, particularly in heterozygous NHPT. Symptomatic ADH patients respond to vitamin D and calcium supplementation but this may increase calciuria and renal complications. PTH treatment can reduce relative hypercalciuria. None of the currently available therapies for ADH, however, prevent tissue calcifications and complications, which may become possible with calcilytics that correct the underlying pathophysiologic defect.\n                  <\/jats:p>","DOI":"10.1530\/eje-15-1028","type":"journal-article","created":{"date-parts":[[2015,12,9]],"date-time":"2015-12-09T08:47:33Z","timestamp":1449650853000},"page":"R189-R208","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":74,"title":["GENETICS IN ENDOCRINOLOGY: Gain and loss of function mutations of the calcium-sensing receptor and associated proteins: current treatment concepts"],"prefix":"10.1093","volume":"174","author":[{"given":"Bernhard","family":"Mayr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schnabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmuth-G\u00fcnther","family":"D\u00f6rr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Sch\u00f6fl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2016031019285164000_174.5.R189.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1154"},{"key":"2016031019285164000_174.5.R189.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01511.x"},{"key":"2016031019285164000_174.5.R189.3","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006-1035"},{"key":"2016031019285164000_174.5.R189.4","doi-asserted-by":"publisher","DOI":"10.1210\/me.2011-1370"},{"key":"2016031019285164000_174.5.R189.5","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2002208"},{"key":"2016031019285164000_174.5.R189.6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.berh.2007.11.006","article-title":"Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations","volume":"22","author":"Egbuna","year":"2008","journal-title":"Best Practice & Research. Clinical Rheumatology"},{"key":"2016031019285164000_174.5.R189.7","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00608.2009"},{"key":"2016031019285164000_174.5.R189.8","doi-asserted-by":"crossref","first-page":"E1146","DOI":"10.1210\/jc.2013-3593","article-title":"A homozygous CaSR mutation causing a FHH phenotype completely masked by vitamin D deficiency presenting as rickets","volume":"99","author":"Szczawinska","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2016031019285164000_174.5.R189.9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1056\/NEJM196403052701001","article-title":"Neonatal familial primary hyperparathyroidism","volume":"270","author":"Hillman","year":"1964","journal-title":"New England Journal of Medicine"},{"key":"2016031019285164000_174.5.R189.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(77)80649-5"},{"key":"2016031019285164000_174.5.R189.11","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1042470"},{"key":"2016031019285164000_174.5.R189.12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.9.2594"},{"key":"2016031019285164000_174.5.R189.13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1999.00729.x"},{"key":"2016031019285164000_174.5.R189.14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2484"},{"key":"2016031019285164000_174.5.R189.15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1306"},{"key":"2016031019285164000_174.5.R189.16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2834"},{"key":"2016031019285164000_174.5.R189.17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118335"},{"key":"2016031019285164000_174.5.R189.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300253"},{"key":"2016031019285164000_174.5.R189.19","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2492"},{"key":"2016031019285164000_174.5.R189.20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1120"},{"key":"2016031019285164000_174.5.R189.21","doi-asserted-by":"publisher","DOI":"10.1038\/ng1194-303"},{"key":"2016031019285164000_174.5.R189.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2011.04142.x"},{"key":"2016031019285164000_174.5.R189.23","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01869.x"},{"key":"2016031019285164000_174.5.R189.24","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.2169\/internalmedicine.52.8375","article-title":"Extrapyramidal symptoms and advanced calcification of the basal ganglia in a patient with autosomal dominant hypocalcemia","volume":"52","author":"Kurozumi","year":"2013","journal-title":"Internal Medicine"},{"key":"2016031019285164000_174.5.R189.25","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.081233"},{"key":"2016031019285164000_174.5.R189.26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.4.1695"},{"key":"2016031019285164000_174.5.R189.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1300278"},{"key":"2016031019285164000_174.5.R189.28","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1029"},{"key":"2016031019285164000_174.5.R189.29","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.040106"},{"key":"2016031019285164000_174.5.R189.30","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000025781.16723.68"},{"key":"2016031019285164000_174.5.R189.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09842-2"},{"key":"2016031019285164000_174.5.R189.32","first-page":"525","article-title":"Autosomal dominant hypocalcemia with mild type 5 Bartter syndrome","volume":"19","author":"Vezzoli","year":"2006","journal-title":"Journal of Nephrology"},{"key":"2016031019285164000_174.5.R189.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(99)00368-3"},{"key":"2016031019285164000_174.5.R189.34","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3345\/kjp.2015.58.4.148","article-title":"Autosomal dominant hypocalcemia with Bartter syndrome due to a novel activating mutation of calcium sensing receptor, Y829C","volume":"58","author":"Choi","year":"2015","journal-title":"Korean Journal of Pediatrics"},{"key":"2016031019285164000_174.5.R189.35","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-011-1871-4"},{"key":"2016031019285164000_174.5.R189.36","doi-asserted-by":"publisher","DOI":"10.1038\/366575a0"},{"key":"2016031019285164000_174.5.R189.37","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1346.044"},{"key":"2016031019285164000_174.5.R189.38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.7.4040"},{"key":"2016031019285164000_174.5.R189.39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199711203372104"},{"key":"2016031019285164000_174.5.R189.40","doi-asserted-by":"crossref","first-page":"e1001436","DOI":"10.1371\/journal.pmed.1001436","article-title":"Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials","volume":"10","author":"Palmer","year":"2013","journal-title":"PLoS Medicine"},{"key":"2016031019285164000_174.5.R189.41","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.beem.2013.02.008","article-title":"Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders","volume":"27","author":"Nemeth","year":"2013","journal-title":"Best Practice & Research. Clinical Endocrinology & Metabolism"},{"key":"2016031019285164000_174.5.R189.42","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1113\/EP085137","article-title":"The calcium-sensing receptor: just one-of-a-kind","volume":"100","author":"Lopez-Fernandez","year":"2015","journal-title":"Experimental Physiology"},{"key":"2016031019285164000_174.5.R189.43","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/jbmr.1838","article-title":"Cinacalcet as adjunctive therapy for hereditary 1,25-dihydroxyvitamin D-resistant rickets","volume":"28","author":"Srivastava","year":"2013","journal-title":"Journal of Bone and Mineral Research"},{"key":"2016031019285164000_174.5.R189.44","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04981107"},{"key":"2016031019285164000_174.5.R189.45","doi-asserted-by":"publisher","DOI":"10.1172\/JCI9038"},{"key":"2016031019285164000_174.5.R189.46","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0022-3565(24)29333-2","article-title":"Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone","volume":"299","author":"Nemeth","year":"2001","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"2016031019285164000_174.5.R189.47","doi-asserted-by":"publisher","DOI":"10.1677\/jme.0.0290015"},{"key":"2016031019285164000_174.5.R189.48","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4155\/fmc.11.17","article-title":"Calcilytics: antagonists of the calcium-sensing receptor for the treatment of osteoporosis","volume":"3","author":"Widler","year":"2011","journal-title":"Future Medicinal Chemistry"},{"key":"2016031019285164000_174.5.R189.49","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bone.2014.04.015","article-title":"AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women","volume":"64C","author":"John","year":"2014","journal-title":"Bone"},{"key":"2016031019285164000_174.5.R189.50","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2015.30"},{"key":"2016031019285164000_174.5.R189.51","doi-asserted-by":"crossref","first-page":"284ra260","DOI":"10.1126\/scitranslmed.aaa0282","article-title":"Calcium-sensing receptor antagonists abrogate airway hyperresponsiveness and inflammation in allergic asthma","volume":"7","author":"Yarova","year":"2015","journal-title":"Science Translational Medicine"},{"key":"2016031019285164000_174.5.R189.52","doi-asserted-by":"crossref","first-page":"e0138384","DOI":"10.1371\/journal.pone.0138384","article-title":"Inhibition of excessive cell proliferation by calcilytics in idiopathic pulmonary arterial hypertension","volume":"10","author":"Yamamura","year":"2015","journal-title":"PLoS One"},{"key":"2016031019285164000_174.5.R189.53","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2174\/1389201016666150505123813","article-title":"Preventing the spread of Alzheimer's disease neuropathology: a role for calcilytics?","volume":"16","author":"Chiarini","year":"2015","journal-title":"Current Pharmaceutical Biotechnology"},{"key":"2016031019285164000_174.5.R189.54","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2836(65)80285-6"},{"key":"2016031019285164000_174.5.R189.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceca.2003.10.020"},{"key":"2016031019285164000_174.5.R189.56","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1002\/jbmr.2551","article-title":"Calcilytic ameliorates abnormalities of mutant calcium-sensing receptor (CaSR) knock-in mice mimicking autosomal dominant hypocalcemia (ADH)","volume":"30","author":"Dong","year":"2015","journal-title":"Journal of Bone and Mineral Research"},{"key":"2016031019285164000_174.5.R189.57","unstructured":"Hannan FM, Nesbit MA, Cranston T, Thakker RV. A calcium-sensing receptor (CaSR) variant, Glu250Lys, present in familial hypocalciuric hypercalcaemia (FHH) and autosomal dominant hypocalcaemic hypercalciuria (ADHH) probands represents a functionally neutral polymorphism: lessons for CaSR mutational analysis. Endocrine Abstracts 2012 28 OC2.8"},{"key":"2016031019285164000_174.5.R189.58","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/dds105"},{"key":"2016031019285164000_174.5.R189.59","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1365-2265.2007.03027.x","article-title":"Correction of hypercalcaemia by cinacalcet in familial hypocalciuric hypercalcaemia","volume":"68","author":"Festen-Spanjer","year":"2008","journal-title":"Clinical Endocrinology"},{"key":"2016031019285164000_174.5.R189.60","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0355"},{"key":"2016031019285164000_174.5.R189.61","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0842"},{"key":"2016031019285164000_174.5.R189.62","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-010-1547-5"},{"key":"2016031019285164000_174.5.R189.63","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2006.01684.x"},{"key":"2016031019285164000_174.5.R189.64","doi-asserted-by":"crossref","first-page":"140050","DOI":"10.1530\/EDM-14-0050","article-title":"Recurrent pancreatitis in a patient with familial hypocalciuric hypercalcaemia treated successfully with cinacalcet","volume":"2014","author":"Gunganah","year":"2014","journal-title":"Endocrinology, Diabetes & Metabolism Case Reports"},{"key":"2016031019285164000_174.5.R189.65","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00431-004-1491-0","article-title":"Neonatal severe hyperparathyroidism: genotype\/phenotype correlation and the use of pamidronate as rescue therapy","volume":"163","author":"Waller","year":"2004","journal-title":"European Journal of Pediatrics"},{"key":"2016031019285164000_174.5.R189.66","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.bone.2014.04.010","article-title":"Novel homozygous inactivating mutation of the calcium-sensing receptor gene (CASR) in neonatal severe hyperparathyroidism-lack of effect of cinacalcet","volume":"64","author":"Atay","year":"2014","journal-title":"Bone"},{"key":"2016031019285164000_174.5.R189.67","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000350540","article-title":"Neonatal hypercalcemia due to a homozygous mutation in the calcium-sensing receptor: failure of cinacalcet","volume":"104","author":"Garcia Soblechero","year":"2013","journal-title":"Neonatology"},{"key":"2016031019285164000_174.5.R189.68","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1515\/jpem-2013-0343","article-title":"A novel CASR mutation associated with neonatal severe hyperparathyroidism transmitted as an autosomal recessive disorder","volume":"27","author":"Diaz-Thomas","year":"2014","journal-title":"Journal of Pediatric Endocrinology & Metabolism"},{"key":"2016031019285164000_174.5.R189.69","first-page":"269","article-title":"Persistent elevated serum levels of intact parathyroid hormone after reoperation for primary hyperparathyroidism and after pamidronate therapy","volume":"45","author":"Darcan","year":"2003","journal-title":"Turkish Journal of Pediatrics"},{"key":"2016031019285164000_174.5.R189.70","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-3209"},{"key":"2016031019285164000_174.5.R189.71","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1687-9856-2012-13","article-title":"A novel CaSR mutation presenting as a severe case of neonatal familial hypocalciuric hypercalcemia","volume":"2012","author":"Tonyushkina","year":"2012","journal-title":"International Journal of Pediatric Endocrinology"},{"key":"2016031019285164000_174.5.R189.72","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/01.pec.0000238747.19477.d3","article-title":"Hypocalciuric hypercalcemia presenting as neonatal rib fractures: a newly described mutation of the calcium-sensing receptor gene","volume":"22","author":"Nyweide","year":"2006","journal-title":"Pediatric Emergency Care"},{"key":"2016031019285164000_174.5.R189.73","doi-asserted-by":"crossref","first-page":"150040","DOI":"10.1530\/EDM-15-0040","article-title":"Successful treatment of neonatal severe hyperparathyroidism with cinacalcet in two patients","volume":"2015","author":"Fisher","year":"2015","journal-title":"Endocrinology, Diabetes & Metabolism Case Reports"},{"key":"2016031019285164000_174.5.R189.74","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2011-0128"},{"key":"2016031019285164000_174.5.R189.75","doi-asserted-by":"crossref","first-page":"P041","DOI":"10.1055\/s-0034-1372058","article-title":"Severe but not neonatally lethal. A homozygous inactivating CaSR mutation in a 3 year old child","volume":"122","author":"Schnabel","year":"2014","journal-title":"Experimental and Clinical Endocrinology & Diabetes"},{"key":"2016031019285164000_174.5.R189.76","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-008-0810-5"},{"key":"2016031019285164000_174.5.R189.77","unstructured":"FDA. FDA Drug Safety Communication: Pediatric clinical studies of Sensipar (cinacalcet hydrochloride) suspended after report of death. 2013. As seen at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm340551.htm."},{"key":"2016031019285164000_174.5.R189.78","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02088.x"},{"key":"2016031019285164000_174.5.R189.79","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.clinthera.2012.03.058","article-title":"Pharmacokinetic and pharmacodynamic properties of the calcimimetic agent cinacalcet (KRN1493) in healthy male Korean subjects: a randomized, open-label, single ascending-dose, parallel-group study","volume":"34","author":"Lee","year":"2012","journal-title":"Clinical Therapeutics"},{"key":"2016031019285164000_174.5.R189.80","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119137"},{"key":"2016031019285164000_174.5.R189.81","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-008-0794-y"},{"key":"2016031019285164000_174.5.R189.82","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8628(19970808)71:2<202::AID-AJMG16>3.0.CO;2-I"},{"key":"2016031019285164000_174.5.R189.83","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1808"},{"key":"2016031019285164000_174.5.R189.84","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2516"},{"key":"2016031019285164000_174.5.R189.85","doi-asserted-by":"publisher","DOI":"10.1002\/humu.20067"},{"key":"2016031019285164000_174.5.R189.86","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2010.04.002"},{"key":"2016031019285164000_174.5.R189.87","doi-asserted-by":"publisher","DOI":"10.1210\/er.2013-1121"},{"key":"2016031019285164000_174.5.R189.88","doi-asserted-by":"publisher","DOI":"10.1210\/me.2009-0041"},{"key":"2016031019285164000_174.5.R189.89","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.phrs.2013.11.006","article-title":"Pharmacoperones and the calcium sensing receptor: exogenous and endogenous regulators","volume":"83","author":"Breitwieser","year":"2014","journal-title":"Pharmacological Research"},{"key":"2016031019285164000_174.5.R189.90","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0129"},{"key":"2016031019285164000_174.5.R189.91","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2007.02896.x"},{"key":"2016031019285164000_174.5.R189.92","doi-asserted-by":"publisher","DOI":"10.1677\/JME-10-0034"},{"key":"2016031019285164000_174.5.R189.93","unstructured":"Babinsky VN, Hannan FM, Howles SA, Nesbit MA, Rust N, Hu J, Spiegel AM & Thakker RV. Calcium-Sensing Receptor (CaSR) Allosteric Modulators Rectify Signal Transduction Abnormalities Associated with G-Protein Alpha-11 (GNA11) Mutations Causing Familial Hypocalciuric Hypercalcemia Type 2 (FHH2) and Autosomal Dominant Hypocalcemia Type 2 (ADH2). In ENDO 2015 - The Endocrine Society's 97th Annual Meeting \u2013 SAT 290-309-Signaling, pp Poster Board SAT-291. San Diego, CA 2015"},{"key":"2016031019285164000_174.5.R189.94","unstructured":"Howles SA, Hannan FM, Babinsky VN, Rogers A, Rust N, Richardson T, McKenna MJ, Nesbit MA & Thakker RV. Cinacalcet is an Effective Therapy for Familial Hypocalciuric Hypercalcemia Type 3 (FHH3) Caused By AP2S1 Mutations. In ENDO 2015 \u2013 The Endocrine Society's 97th Annual Meeting \u2013 SAT 290-309-Signaling, pp Poster Board SAT-293. San Diego, CA 2015"},{"key":"2016031019285164000_174.5.R189.95","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1515\/JPEM.2005.18.7.689","article-title":"A family with autosomal dominant hypocalcaemia with hypercalciuria (ADHH): mutational analysis, phenotypic variability and treatment challenges","volume":"18","author":"Burren","year":"2005","journal-title":"Journal of Pediatric Endocrinology & Metabolism"},{"key":"2016031019285164000_174.5.R189.96","doi-asserted-by":"publisher","DOI":"10.1210\/jc.87.7.3068"},{"key":"2016031019285164000_174.5.R189.97","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020081"},{"key":"2016031019285164000_174.5.R189.98","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000303188","article-title":"Phenotypic variation in a large family with autosomal dominant hypocalcaemia","volume":"74","author":"Sorheim","year":"2010","journal-title":"Hormone Research in P\u00e6diatrics"},{"key":"2016031019285164000_174.5.R189.99","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/apa.12743","article-title":"Activating calcium-sensing receptor gene variants in children: a case study of infant hypocalcaemia and literature review","volume":"103","author":"Thim","year":"2014","journal-title":"Acta Paediatrica"},{"key":"2016031019285164000_174.5.R189.100","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199610103351505"},{"key":"2016031019285164000_174.5.R189.101","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3430"},{"key":"2016031019285164000_174.5.R189.102","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.50.91"},{"key":"2016031019285164000_174.5.R189.103","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1515\/JPEM.2008.21.4.385","article-title":"Autosomal dominant hypoparathyroidism with severe hypomagnesemia and hypocalcemia, successfully treated with recombinant PTH and continuous subcutaneous magnesium infusion","volume":"21","author":"Sanda","year":"2008","journal-title":"Journal of Pediatric Endocrinology & Metabolism"},{"key":"2016031019285164000_174.5.R189.104","first-page":"745","article-title":"Successful pregnancy outcome in a woman with a gain-of-function mutation of the calcium-sensing receptor. A case report","volume":"44","author":"Gherman","year":"1999","journal-title":"Journal of Reproductive Medicine"},{"key":"2016031019285164000_174.5.R189.105","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.4158\/EP12132.CR","article-title":"Recombinant human parathyroid hormone therapy (1-34) in an adult patient with a gain-of-function mutation in the calcium-sensing receptor-a case report","volume":"19","author":"Gonzales","year":"2013","journal-title":"Endocrine Practice"},{"key":"2016031019285164000_174.5.R189.106","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2605"},{"key":"2016031019285164000_174.5.R189.107","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M609045200"},{"key":"2016031019285164000_174.5.R189.108","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M413403200"},{"key":"2016031019285164000_174.5.R189.109","doi-asserted-by":"publisher","DOI":"10.1210\/en.2012-1887"},{"key":"2016031019285164000_174.5.R189.110","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1974"},{"key":"2016031019285164000_174.5.R189.111","doi-asserted-by":"crossref","first-page":"e115178","DOI":"10.1371\/journal.pone.0115178","article-title":"Amino alcohol- (NPS-2143) and quinazolinone-derived calcilytics (ATF936 and AXT914) differentially mitigate excessive signalling of calcium-sensing receptor mutants causing Bartter syndrome type 5 and autosomal dominant hypocalcemia","volume":"9","author":"Letz","year":"2014","journal-title":"PLoS One"},{"key":"2016031019285164000_174.5.R189.112","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0714"},{"key":"2016031019285164000_174.5.R189.113","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0651"},{"key":"2016031019285164000_174.5.R189.114","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1210\/en.2015-1269","article-title":"The calcilytic agent NPS 2143 rectifies hypocalcemia in a mouse model with an activating calcium-sensing-receptor (CaSR) mutation: relevance to autosomal dominant hypocalcemia type 1 (ADH1)","volume":"156","author":"Hannan","year":"2015","journal-title":"Endocrinology"},{"key":"2016031019285164000_174.5.R189.115","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1186\/1752-1947-5-564","article-title":"Clinical and biochemical outcomes of cinacalcet treatment of familial hypocalciuric hypercalcemia: a case series","volume":"5","author":"Rasmussen","year":"2011","journal-title":"Journal of Medical Case Reports"},{"key":"2016031019285164000_174.5.R189.116","unstructured":"Scharla SH, Lempert UG. Coincidence of familial hypocalciuric hypercalcemia and parathyroid adenoma: therapeutic effect of cinacalcet. In 52.Symposion der Deutschen Gesellschaft f\u00fcr Endokrinologie (DGE). Gie\u00dfen, Germany, 2009"},{"key":"2016031019285164000_174.5.R189.117","doi-asserted-by":"crossref","first-page":"P038","DOI":"10.1055\/s-0034-1372055","article-title":"CaSR mutants disrupting the disulfide bond between C582 and C568 in the cysteine-rich domain of the CaSR do not act as dominant negative mutants","volume":"122","author":"Letz","year":"2014","journal-title":"Experimental and Clinical Endocrinology & Diabetes"},{"key":"2016031019285164000_174.5.R189.118","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1472-6823-14-81","article-title":"A novel mutation in calcium-sensing receptor gene associated to hypercalcemia and hypercalciuria","volume":"14","author":"Mastromatteo","year":"2014","journal-title":"BMC Endocrine Disorders"},{"key":"2016031019285164000_174.5.R189.119","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1210\/jc.2015-1518","article-title":"Cinacalcet treatment in an adolescent with concurrent 22q11.2 deletion syndrome and FHH3 caused by AP2S1 mutation","volume":"100","author":"Tenhola","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2016031019285164000_174.5.R189.120","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-010-1335-z"},{"key":"2016031019285164000_174.5.R189.121","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1007\/s12098-014-1442-3","article-title":"Neonatal severe hyperparathyroidism due to compound heterozygous mutation of calcium sensing receptor (CaSR) gene presenting as encephalopathy","volume":"81","author":"Kulkarni","year":"2014","journal-title":"Indian Journal of Pediatrics"},{"key":"2016031019285164000_174.5.R189.122","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.159228"},{"key":"2016031019285164000_174.5.R189.123","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M200978200"},{"key":"2016031019285164000_174.5.R189.124","unstructured":"Letz S, Haag C, Schulze E, Frank-Raue K, Mayr B, Raue F, Sch\u00f6fl C. Five novel inactivating mutations of the calcium-sensing receptor: the calcimimetic NPS R-568 increases signal transduction of mutant receptors. In 54.Symposion der Deutschen Gesellschaft f\u00fcr Endokrinologie (DGE). Hamburg, Germany, 2011"},{"key":"2016031019285164000_174.5.R189.125","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1076"},{"key":"2016031019285164000_174.5.R189.126","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00223-009-9298-7","article-title":"Residue 826 in the calcium-sensing receptor is implicated in the response to calcium and to R-568 calcimimetic compound","volume":"86","author":"Alvarez-Hernandez","year":"2010","journal-title":"Calcified Tissue International"},{"key":"2016031019285164000_174.5.R189.127","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M400724200"},{"key":"2016031019285164000_174.5.R189.128","first-page":"P01_01","article-title":"Teriparatide as a novel therapeutic option in the treatment of ADH \u2013 a case report","volume":"123","author":"Schellhaas","year":"2015","journal-title":"Experimental and Clinical Endocrinology & Diabetes"},{"key":"2016031019285164000_174.5.R189.129","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12056"},{"key":"2016031019285164000_174.5.R189.130","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M308010200"},{"key":"2016031019285164000_174.5.R189.131","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bone.2013.05.021","article-title":"Characterization of the effect of chronic administration of a calcium-sensing receptor antagonist, ronacaleret, on renal calcium excretion and serum calcium in postmenopausal women","volume":"56","author":"Caltabiano","year":"2013","journal-title":"Bone"},{"key":"2016031019285164000_174.5.R189.132","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2855"},{"key":"2016031019285164000_174.5.R189.133","doi-asserted-by":"crossref","unstructured":"Cosman F Gilchrist N McClung M Foldes J de Villiers T Santora A Leung A Samanta S Heyden N McGinnis JP II . A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates. Osteoporosis International 2015 doi:10.1007\/s00198-015-3392-7).","DOI":"10.1007\/s00198-015-3392-7"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/174\/5\/R189.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/174\/5\/R189.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T14:32:57Z","timestamp":1748701977000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/174\/5\/R189\/6655068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":133,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.1530\/eje-15-1028","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}